AAVLife aavlife.com


Public lists: Rare Diseases (230)

AAVLife, registered in Paris, is a privately held company dedicated to advancing gene therapy for rare diseases. AAVLife's lead indication is for Friedreich's Ataxia Cardiomyopathy. Its program is based on the successful use of a gene-therapy approach in a mouse model developed to mimic the gene defect and cardiac symptoms of Friedreich's Ataxia. The approach made use of an adeno-associated virus (AAV) to introduce a normal gene into cardiac tissue. The therapy restored cardiac function and reve...Show all

AAVLife, registered in Paris, is a privately held company dedicated to advancing gene therapy for rare diseases. AAVLife's lead indication is for Friedreich's Ataxia Cardiomyopathy. Its program is based on the successful use of a gene-therapy approac...Show all

Company (Alive / Active)

Phone: +33 6 79 53 24 46

Fax:

183 Avenue de Choisy

75013
France

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
AAVLife $12M Apr 15, 2014

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related AAVLife Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 2 investors

Board Members

Competitors

Company Status Description Investors

Audentes Therapeutics

San Francisco, California, United States
IPO / Went publicAudentes is a biotechnology company committed to the development and commercialization of treatments for people with serious, rare diseases through the application of AAV gene therapy technology. The company has three products in development, AT001 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT002 for the treatment of Pompe disease, and AT003 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).Login to see details

Patents

Title Application Date Patent Date Status
(Patent / Application)